Kerin M J, McAnena O J, O'Malley V P, Grimes H, Given H F
University Department of Surgery, University College Hospital, Galway, Ireland.
Br J Surg. 1989 Aug;76(8):838-9. doi: 10.1002/bjs.1800760826.
There is increasing interest in the potential role of monoclonal antibodies as tumour markers in the early detection of metastatic disease. CA15-3 is a circulating antigen which is relatively specific for breast tissue and defined by two monoclonal antibodies. It is elevated in the serum of patients with breast cancer but its relationship to clinical stage and tumour progression has not been well defined. CA15-3 levels have been measured in a consecutive series of 97 patients with breast cancer at the time of diagnosis and at 3-monthly intervals thereafter. All patients have been evaluated and followed by using routine biochemical and radiological parameters to detect occult metastatic disease. There was no difference between a control group of patients who presented with benign disease (n = 18: means(s.d.) 18.0(5.1) units/ml): and those who presented with stage I disease (n = 37: 18.4(5.3) units/ml) or stage II disease (n =21: 18.0(4.0) units/ml). Patients with stage III disease (n = 23: 32.0(10.4) units/ml) had significantly elevated levels of CA15-3 compared with those in stage I (P less than 0.001). All patients with documented metastatic disease at presentation or at follow-up had markedly elevated CA15-3 levels (n = 10: 155.8(50.2) units/ml). CA15-3 is a reliable tumour marker in patients with advanced disease.
单克隆抗体作为肿瘤标志物在转移性疾病早期检测中的潜在作用越来越受到关注。CA15 - 3是一种循环抗原，对乳腺组织具有相对特异性，由两种单克隆抗体定义。它在乳腺癌患者血清中升高，但其与临床分期和肿瘤进展的关系尚未明确界定。对97例乳腺癌患者在诊断时及之后每3个月进行一次CA15 - 3水平测定。所有患者均采用常规生化和放射学参数进行评估和随访，以检测隐匿性转移性疾病。患有良性疾病的对照组患者（n = 18：均值（标准差）18.0（5.1）单位/毫升）与患有I期疾病的患者（n = 37：18.4（5.3）单位/毫升）或II期疾病的患者（n = 21：18.0（4.0）单位/毫升）之间无差异。与I期患者相比，III期疾病患者（n = 23：32.0（10.4）单位/毫升）的CA15 - 3水平显著升高（P小于0.001）。所有在就诊时或随访时有记录的转移性疾病患者的CA15 - 3水平均明显升高（n = 10：155.8（50.2）单位/毫升）。CA15 - 3是晚期疾病患者可靠的肿瘤标志物。
